Mantle Cell Lymphoma

More tailored selection processes, which have placed a greater emphasis on patient-specific characteristics, such as risk and genomic status, and made possible with a growing number of treatment options, have led to optimized therapeutic decisions for patients with hematologic malignancies.

Anita Kumar, MD, discusses future directions with pirtobrutinib in mantle cell lymphoma.

For patients with mantle cell lymphoma who have progressed after treatment with a BTK inhibitor such as ibrutinib, there is an unmet need for the development of safe and effective targeted therapies to improve otherwise dismal outcomes.

Anita Kumar, MD, discusses efforts made to address areas of unmet need in mantle cell lymphoma.

Peter Martin, MD, discusses the importance of designing clinical trials for real-world utility in mantle cell lymphoma.

Acalabrutinib monotherapy continued to be highly active and safe in patients with relapsed/refractory mantle cell lymphoma with longer-term follow-up.

Anita Kumar, MD, discusses navigating CAR T-cell therapy–related toxicities in mantle cell lymphoma.

The combination of loncastuximab tesirine-lpyl and ibrutinib displayed encouraging antitumor activity with a manageable safety profile in patients with relapsed/refractory diffuse large B-cell lymphoma and mantle cell lymphoma.

Jae Park, MD, discusses the factors to consider when selecting among the available CAR T-cell therapies for the treatment of patients with mantle cell lymphoma.

Anita Kumar, MD, discusses the improved efficacy of venetoclax when used in combination with ibrutinib compared with venetoclax or ibrutinib alone in mantle cell lymphoma. 

Anita Kumar, MD, discusses patient factors to consider when selecting treatment in relapsed/refractory mantle cell lymphoma.

Tycel Jovelle Phillips, MD, discusses the future of CAR T-cell therapy in mantle cell lymphoma patients.

Mitchell R. Smith, MD, PhD, discusses the patient population of the phase 2 ECOG-ACRIN E1411 trial in mantle cell lymphoma.

Health Canada has approved the BTK inhibitor zanubrutinib for use in the treatment of adult patients with mantle cell lymphoma who have previously received at least 1 therapy.

The addition of venetoclax to lenalidomide and rituximab resulted in a high response rate and encouraging minimal residual disease undetectability in patients with newly diagnosed mantle cell lymphoma—even in those with high-risk features.

Mitchell R. Smith, MD, PhD, discusses the results of the ECOG-ACRIN E1411 trial examining BR-based induction treatment in patients with mantle cell lymphoma and next steps for research.

Mitchell R. Smith, MD, PhD, discusses the rationale for the phase 2 ECOG-ACRIN E1411 trial in mantle cell lymphoma.

This article discusses the current treatment landscape and therapeutic strategies for mantle cell lymphoma, the role of Bruton tyrosine kinase inhibitor therapies in MCL, and insights on new regimens and ongoing clinical trials from leading experts in hematologic malignancies.

Peter Martin, MD, discusses the role of maintenance therapy with rituximab in mantle cell lymphoma.

Bijal Shah, MD, MS, discusses efforts to combat resistance to BTK inhibitors in patients with mantle cell lymphoma.

Tycel Jovelle Phillips, MD, discusses the next steps in evaluating the combination of venetoclax, lenalidomide, and rituximab in mantle cell lymphoma.

The FDA has granted a breakthrough therapy designation orelabrutinib for the treatment of patients with relapsed/refractory mantle cell lymphoma.

Three first-in-class, SOX11 small molecule inhibitors demonstrated on-target antitumor activity in mantle cell lymphoma cell lines and in patient-derived ibrutinib-resistant models ex vivo.

Peter Martin, MD, discusses the findings of a real-world analysis of clinical outcomes in mantle cell lymphoma.

Peter Martin, MD, discusses discrepancies in real-world patterns of care for patients with MCL and what can be done to overcome them.